RT Journal Article SR Electronic T1 High concordance of 70-gene recurrence risk signature and 80-gene molecular subtyping signature between core needle biopsy and surgical resection specimens in early-stage breast cancer JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.05.28.21257887 DO 10.1101/2021.05.28.21257887 A1 Jennifer A. Crozier A1 Julie Barone A1 Pat Whitworth A1 Abraham Cheong A1 Robert Maganini A1 Jeffrey Falk A1 Jia-Perng Wei A1 Sammy Mee A1 Jake Ruby A1 Suoyi Yang A1 Yen Huynh A1 Anke Witteveen A1 Christine Finn A1 Kate Corcoran A1 Christa Dreezen A1 Patricia Dauer A1 Andrea Menicucci A1 Shiyu Wang A1 Annie Tran A1 Erin Yoder A1 Bastiaan van der Baan A1 William Audeh A1 Annuska Glas A1 FLEX Investigators Group YR 2021 UL http://medrxiv.org/content/early/2021/06/02/2021.05.28.21257887.abstract AB Introduction With an increase in neoadjuvant therapy recommendations for most early-stage breast cancer patients due to the COVID-19 pandemic, it has become increasingly imperative to ensure that molecular diagnostic assays provide reliable results from preoperative core needle biopsies. Therefore, the objective of this study was to determine the concordance of MammaPrint results (70-gene signature) and BluePrint results (80-gene signature) between core needle biopsies (CNB) and surgical resection (SR) specimens using prospectively collected matched tissues from patients enrolled in the FLEX trial (NCT03053193).Methods We analyzed 113 matched CNB and SR tumor specimens from women with early-stage breast cancer enrolled in the FLEX trial. Each patient enrolled in the trial receives a MammaPrint recurrence risk classification test with or without BluePrint molecular subtyping. Concordance of MammaPrint is reported using overall percentage agreement, positive predictive value (PPV, High Risk), negative predictive value (NPV, Low Risk), and Cohen’s kappa coefficient. Additionally, correlations between sample types are reported using Pearson correlation coefficient.Results We found good concordance for MammaPrint results between CNB and SR tumor samples (90.3%, κ = 0.803), with a 95.1% NPV and 84.6% PPV. There was also a strong correlation of MammaPrint indices between CNB and SR specimens (r = 0.94). In addition to our primary objective, we determined the concordance of BluePrint subtyping in the matched tumor samples, and found excellent concordance (98.2%) and strong correlation of BluePrint scores within each subtype.Conclusion CNB samples demonstrated overall high concordance with paired SR samples for MammaPrint risk classification, ensuring that physicians are provided with accurate prognostic information for therapy decisions based on testing of core biopsy tissue. Further, BluePrint molecular subtyping also had good concordance between the sample types, outperforming concordance rates based on traditional IHC based classification. Overall, with an increase in neoadjuvant therapy, physicans and patients can be assured that MammaPrint and BluePrint provide reliable results that guide timely and appropriate therapies using preoperative CNB specimens.Competing Interest StatementJAC, JB, PW, AC, and RM are FLEX principal investigators and have contracted research with Agendia Inc. JAC and RM receives honoraria as part of Speakers Bureau for Agendia Inc. JF, JW, SM, JR, SY, YH, CF, KC, PD, AM, SW, AT, EY, and WA, are non-commercial employees of Agendia Inc, Irvine, CA. AW, CD, BB, and AG are non-commercial employees of Agendia NV, Amsterdam, NL. No other disclosures were reported. AG is a co-inventor of the BluePrint 80-gene signature and is a full-time employee of Agendia, NV (patent numbers: 9175351, 10072301).Clinical TrialNCT03053193Funding StatementThis study is supported by Agendia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was approved by Institutional Review Boards at all participating sites and registered with ClinicalTrials.gov (NCT03053193). This research study was reviewed and approved by the following institutions: Jennifer Crozier at Baptist Health IRB (Jacksonville, FL; #18-03); Julie Barone at SCL Health IRB (Denver, CO; FWA: 00029722); Pat Whitworth at WCG IRB (Nashville, TN; IRB TN: 20170039); Abraham Cheong at WIRB (Brunswick, GA; IRB TN: 20170039); Robert Maganini at WIRB (Bartlett, IL; IRB TN: 20170039); Jose Perez-Tamayo at WCG IRB (Ogden, UT; IRB TN: 20170039). All patients gave informed, written consent through an approved IRB informed consent form in order to participate in this clinical research study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe clinical datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Raw array data have not been made publicly available as part of a collaboration agreement with the diagnostic company Agendia Inc.